Drugs / KF-0210
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04713891 | Mar 2021 → Dec 2022 | colorectal cancer, esophageal squamous cell carcinoma, gastric cancer, lung cancer +1 | Keythera Pharmaceuticals (Australia) Pty Ltd | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KF-0210 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04713891 ↗ |
| Route | Oral | “orally administered” NCT04713891 ↗ |